Navigation Links
Research suggests new cause to blame for spinal muscular atrophy
Date:6/21/2012

CHAPEL HILL, NC Over 15 years ago, researchers linked a defect in a gene called survival motor neuron -- or SMN -- with the fatal disease spinal muscular atrophy. Because SMN had a role in assembling the intracellular machinery that processes genetic material, it was assumed that faulty processing was to blame.

Now, University of North Carolina scientists have discovered that this commonly held assumption is wrong and that a separate role of the SMN gene still not completely elucidated -- is likely responsible for the disease's manifestations. The research appears Thursday June 21, 2012 in the journal Cell Reports.

"There are a number of gene therapies and RNA therapies in the pipeline that may still work regardless of the underlying cause of the disease," said senior study author Gregory Matera, PhD, professor in the departments of biology and genetics and a member of the Program in Molecular Biology and Biotechnology in the UNC School of Medicine.

"But if those approaches don't pan out, it could be that the therapy isn't reaching the precise tissues where defective SMN is most damaging," he added. "Our result is exciting because we now have a starting point to uncover what is truly causing this disease so we can more effectively treat it."

Spinal muscular atrophy is characterized by muscle weakness and wasting (atrophy) resulting from the progressive loss of motor neurons in the spinal cord. The disease is due to a partial loss of function in the SMN gene that normally loads up the "splicing" machinery with the proteins necessary for cutting and pasting the cell's genetic instructions together. Cells that completely lack SMN fail to correctly generate and process the genetic blueprint for the proteins needed to carry out the rest of the body's activities.

But in addition to roles in splicing, SMN has been implicated in a number of other processes that occur only in specific tissues, such as the formation of the junction between muscle and nerve cells or the maintenance of muscle architecture. Thus Matera and his colleagues wondered if defective splicing was really responsible for spinal muscular atrophy or if one of these tissue-specific roles was the cause.

In this study, the researchers investigated whether they could disconnect SMN's "primary" role in splicing from the physical characteristics typical of spinal muscular atrophy. To do so, they first created fruit flies carrying the same genetic mutation that causes the disease. The mutant flies didn't survive to the larval stage and showed significant defects in locomotion as well as reductions in those important splicing proteins.

But when the researchers re-introduced functional SMN, only the larval lethality and locomotor defects -- not the level of splicing factors --were rescued. Therefore, this splicing function of SMN is not a major contributor to spinal muscular atrophy. Right now Matera and colleagues are using a number of highly sophisticated "omics" methods such as proteomics and RNomics to pin down the real culprit.


'/>"/>

Contact: Les Lang
llang@med.unc.edu
919-966-9366
University of North Carolina Health Care
Source:Eurekalert

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Researchers tune the strain in graphene drumheads to create quantum dots
3. Graphene Research: Trapping light in a carbon net
4. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
5. Cetero Research Announces Executive Appointments and New Company Name
6. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
7. Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs
8. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
9. Auxogyn And Reproductive Medicine Associates of New Jersey Partner To Advance in vitro fertilization Research
10. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... NEW YORK , March 23, 2017 ... ... causes of death, putting significant strain on health care systems, ... of cancer diagnoses rises, so too does the development of ... with minimum side effects. Among the many types of cancer ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... Mass. (PRWEB) , ... March 22, 2017 , ... ... scale up human tissue regeneration from small lab samples to full-size tissues, bones, ... how to establish a vascular system that delivers blood deep into the developing ...
Breaking Biology Technology:
(Date:2/21/2017)... N.Y. and PORTLAND, Ore. ... ) and the Avamere Family of Companies (Avamere Health ... today announced a six-month research study that will apply ... improve eldercare at senior living and health centers. By ... Avamere hopes to gain insights into physical and environmental ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):